Funding for this research was provided by:
Gilead Sciences (V-2911)
Received: 14 July 2021
Accepted: 27 September 2021
First Online: 12 October 2021
: The ethical committee approved the study protocol of Ziekenhuis Oost-Limburg on August 23, 2018 (18/0012U). The study protocol is registered at clinicaltrials.gov (NCT04251572). The study was conducted in accordance with the provisions of the Declaration of Helsinki and its amendments. Good clinical practice guidelines were followed throughout the study and all participants provided written informed consent.
: Not applicable.
: DB has received travel grants from AbbVie and Gilead Sciences and research grants from Gilead Sciences; RB has received travel grants from AbbVie, Gilead Sciences and Merck Sharp & Dohme (MSD) and research grants from Gilead and MSD; OK has received a travel grant from Gilead Sciences and research grants from Gilead Sciences and CyTuVax BV; FN has received research grants, consultancy agreements and travel grants in relationship with this manuscript from AbbVie en Gilead; MH has received advisory boards fees and lecture fees from Gilead, AbbVie, and MSD; OD has received research support from AbbVie, Gilead and MSD/MERCK; GR has received research grants from AbbVie, Janssen Pharmaceuticals, MSD, and consultancy agreements for AbbVie, BMS, Gilead Sciences and MSD. All other co-authors report no competing interests.